Antifungal activity of extracts of some plants used in Brazilian traditional medicine against the pathogenic fungus Paracoccidioides brasiliensis.

Laboratório de Química dos Produtos Naturais, Centro de Pesquisas René Rachou, Fiocruz, Belo Horizonte, MG, Brazil.
Pharmaceutical Biology (Impact Factor: 1.21). 04/2010; 48(4):388-96. DOI:10.3109/13880200903150385
Source: PubMed

ABSTRACT Paracoccidioidomycosis (PCM) is a systemic granulomatous disease caused by Paracoccidioides brasiliensis Almeida (Onygenales) that requires 1-2 years of treatment. In the absence of drug therapy, the disease is usually fatal, highlighting the need for the identification of safer, novel, and more effective antifungal compounds. With this need in mind, several plants employed in Brazilian traditional medicine were assayed on P. brasiliensis and murine macrophages. Extracts were prepared from 10 plant species: Inga spp. Mill. (Leguminosae), Schinus terebinthifolius Raddi (Anacardiaceae), Punica granatum L. (Punicaceae), Alternanthera brasiliana Kuntze (Amaranthaceae), Piper regnellii CDC. (Piperaceae), P. abutiloides Kunth (Piperaceae), Herissantia crispa L. Briz. (Malvaceae), Rubus urticaefolius Poir (Rosaceae), Rumex acetosa L. (Polygonaceae), and Baccharis dracunculifolia DC. (Asteraceae). Hexane fractions from hydroalcoholic extracts of Piper regnellii and Baccharis dracunculifolia were the most active against the fungus, displaying minimum inhibitory concentration (MIC) values of 7.8 microg/mL and 7.8-30 mug/mL, respectively. Additionally, neither of the extracts exhibited any apparent cytotoxic effects on murine macrophages at 20 microg/mL. Analyses of these fractions using gas chromatography-mass spectrometry (GC-MS) showed that the major components of B. dracunculifolia were ethyl hydrocinnamate (14.35%) and spathulenol (16.02%), while the major components of the hexane fraction of Piper regnellii were 1-methoxy-4-(1-propenyl) benzene (21.94%) and apiol (21.29%). The activities of these fractions against P. brasiliensis without evidence of cytotoxicity to macrophages justify their investigation as a potential source of new chemical agents for the treatment of PCM.

0 0
  • [show abstract] [hide abstract]
    ABSTRACT: MIC assays against Paracoccidioides brasiliensis, the etiological agent of paracoccidioidomycosis, had been conducted with variable protocols, both employing macrodilution or microdilution tests, and including differences in inoculum preparation, media used, incubation periods and temperatures. Twenty-one clinical and environmental isolates of Paracoccidioides spp. were tested using amphotericin B, itraconazole, ketoconazole, fluconazole, sulfamethoxazole, sulfamethoxazole-trimethoprim and terbinafine, according to the CLSI (M27-A2 document) with modifications such as three media formulations: RPMI 1640, McVeigh & Morton (MVM) and Modified Mueller-Hinton (MMH); two incubation temperatures: room temperature (25-28°C) and 37°C; and three incubation periods: 7, 10 and 15 days. The antifungal activities were also classified as fungicidal or fungistatic. The best results were obtained after 15 days of incubation which was chosen as the standard incubation time. The MICs for most individual isolates grown for the same length of time at the same temperature varied with the different media used (P<0.05). Of the isolates, 81% showed transition from the yeast to the mycelial form in RPMI medium at 37°C, independent of the presence of antifungals. MMH medium appears to be a suitable medium for susceptibility testing of antifungal drugs with P. brasiliensis, except for sulfametoxazole and the combination of sulfamethoxazole-trimethoprim, where the MVM medium presented better results. The incubation temperature influenced the MICs with, in general, higher MIC values at 25°C (mycelia form) than at 37°C (P<0.05). Based on our results we tentatively propose a microdilution assay protocol for susceptibility testing of antifungal drugs against Paracoccidioides.
    Journal of clinical microbiology 11/2012; · 4.16 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Paracoccidioidomycosis is a prevalent systemic mycosis in Latin America which requires prolonged treatment with highly toxic antifungals. Baccharis dracunculifolia is a medicinal plant in Brazil that is a candidate in the search for new drugs. Fractions of the hexanic extracts were obtained using chromatographic procedures and assessed using an antifungal assay with Paracoccidioides brasiliensis (Pb18), tumor cell lines and amastigote forms of Leishmania, L. amazonensis. Four compounds were isolated, i.e., ursolic acid (1), methyl linolenate (2), caryophyllene oxide (3), and trans-nerolidol (4). Compounds 2, 3 and 4 displayed antifungal activity against four isolates of Paracocci dioides with MIC values ranging from 3.9-250 μg/ml. Only caryophyllene oxide showed differences in the MIC values against Pb18 when the medium was supplemented with ergosterol, which suggested that the compound interacts with ergosterol. Ursolic acid was active in the cytotoxic assays and showed leishmanicidal activity. Scanning electron microscopy demonstrated that compounds 2, 3 and 4 decreased the cell size and produced an irregular cell wall surface on P. brasiliensis cells. The present results showed the biological activities of the isolated compounds and revealed that these compounds may affect the cell surface and growth of P. brasiliensis isolates.
    Medical mycology: official publication of the International Society for Human and Animal Mycology 05/2012; 50(8):843-51. · 2.13 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: The M27-A3 method is not available for use with dimorphic fungi, such as those of the Paracoccidioides genus. In this study, we developed a microdilution method and added the alamarBlue® reagent to test the responses of P. brasiliensis and P. lutzii against amphotericin B and itraconazole antifungals. The test proved to be sensitive, practical and inexpensive and can be used to monitor the activity of low-growth microorganisms and their response to various drugs.
    Journal of clinical microbiology 01/2013; · 4.16 Impact Factor